Lantheus (LNTH) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research cut shares of Lantheus (NASDAQ:LNTH) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning, Zacks.com reports.

According to Zacks, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States. “

A number of other analysts also recently issued reports on LNTH. BidaskClub upgraded Lantheus from a buy rating to a strong-buy rating in a research report on Friday, February 22nd. ValuEngine lowered Lantheus from a buy rating to a hold rating in a research note on Wednesday, January 2nd. Finally, TheStreet upgraded Lantheus from a c+ rating to a b rating in a research note on Monday, March 4th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $23.33.

Shares of LNTH stock traded down $0.23 during mid-day trading on Wednesday, reaching $24.73. 3,102 shares of the company’s stock traded hands, compared to its average volume of 260,002. Lantheus has a 12 month low of $12.59 and a 12 month high of $26.30. The stock has a market cap of $948.33 million, a PE ratio of 26.30, a price-to-earnings-growth ratio of 1.79 and a beta of 1.59. The company has a current ratio of 3.70, a quick ratio of 3.08 and a debt-to-equity ratio of 3.71.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Tuesday, February 19th. The medical equipment provider reported $0.24 EPS for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.09. Lantheus had a net margin of 11.80% and a return on equity of 73.07%. The firm had revenue of $86.27 million for the quarter, compared to analysts’ expectations of $83.93 million. During the same quarter in the previous year, the business posted $2.47 EPS. The company’s quarterly revenue was up 6.2% on a year-over-year basis. On average, sell-side analysts forecast that Lantheus will post 1.15 earnings per share for the current fiscal year.

In other Lantheus news, CEO Mary Anne Heino sold 15,799 shares of Lantheus stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $25.40, for a total value of $401,294.60. Following the transaction, the chief executive officer now owns 684,402 shares in the company, valued at $17,383,810.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Cesare Orlandi sold 3,060 shares of Lantheus stock in a transaction dated Thursday, January 31st. The shares were sold at an average price of $16.56, for a total value of $50,673.60. Following the completion of the transaction, the insider now owns 77,746 shares in the company, valued at approximately $1,287,473.76. The disclosure for this sale can be found here. Insiders sold 75,062 shares of company stock worth $1,699,814 in the last quarter. 2.60% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Creative Planning purchased a new position in Lantheus in the first quarter valued at about $447,000. First Quadrant L P CA acquired a new position in Lantheus in the first quarter valued at approximately $95,000. Nkcfo LLC acquired a new position in Lantheus in the first quarter valued at approximately $206,000. Meeder Asset Management Inc. lifted its holdings in Lantheus by 212.8% in the first quarter. Meeder Asset Management Inc. now owns 4,757 shares of the medical equipment provider’s stock valued at $115,000 after acquiring an additional 3,236 shares during the period. Finally, OmniStar Financial Group Inc. acquired a new position in Lantheus in the first quarter valued at approximately $299,000. Institutional investors own 93.10% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Read More: Cost of Capital Explained

Get a free copy of the Zacks research report on Lantheus (LNTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.